Matinas BioPharma (MTNB) Q2 2024 earnings summary

Executive summary

• Signed a non-binding term sheet for global licensing of MAT2203, targeting invasive aspergillosis and other indications, with ongoing partnership discussions and positive compassionate use results in 31 patients.

• LNC platform advances include promising preclinical results in oncology and inflammation, though further optimization is needed for product candidates.

• No product revenue has been generated; operations are funded primarily through equity offerings and collaborations.

• Net loss for the six months ended June 30, 2024 was $11.5 million, similar to the prior year period.

• Substantial doubt exists about the ability to continue as a going concern beyond the next twelve months without additional funding.

Financial highlights

• Net loss for Q2 2024 was $5.7 million ($0.02/share), improved from $6.1 million ($0.03/share) in Q2 2023.

• No revenue reported in Q2 2024 or Q2 2023; six-month revenue was $0 in 2024 vs. $1.1 million in 2023 from prior collaborations.

• Six-month net loss for 2024 was $11.5 million ($0.05/share), nearly flat versus $11.6 million ($0.05/share) in 2023.

• Cash, cash equivalents, and marketable securities totaled $14.3 million as of June 30, 2024, up from $13.8 million at year-end 2023, reflecting a $10 million capital raise.

• Research and development and administrative expenses decreased year-over-year.

Outlook and guidance

• Confident in finalizing a definitive MAT2203 partnership agreement soon, with upfront payment, milestones, royalties, and clinical cost-sharing expected.

• ORALTO phase III trial for MAT2203 anticipated to initiate in Q4 2024, with first patient likely in 2025; enrollment projected to take 24 months.

• Further guidance on LNC platform development expected after MAT2203 partnership is secured.

• Current cash resources are not sufficient to fund operations beyond the next twelve months; additional capital will be required.

• The company is exploring public and private equity, debt, and partnership opportunities to secure funding.